US4892865A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents
Assignee: MICHIGAN ANN ARBOR MICHIGAN A CONSTITUTIONAL CORP OF MICHIGAN, University of, Regents of
•
Filing: 1987-12-01
•
Granted: 1990-01-09
•
Expires: 2007-12-01
Abstract
Abstract This invention relates to the use of certain substituted pyrrolo[2,3-d]-pyrimidine nucleosides in the treatment of viral infections, in particular those caused by human immunodeficiency virus type 1, herpes simplex virus type 1 and human cytomegalovirus. These substituted compounds retain antiviral properties present in their parent compounds yet exhibit significantly decreased levels of cytotoxicity.
Inventors
- 👤 Leroy B. Townsend
- 👤 John C. Drach
- 👤 Steven H. Krawczyk
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 22:19
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/16
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
79 words
The method of treating human cells infected with a virus selected from the group consisting of herpes virus and cytomegalovirus, said method comprising the step of contacting said cells with a composition comprising a therapeutically effective amount of a compound selected from the group consisting of a compound of the following formula and pharmaceutically acceptable salts thereof: ##STR5## where R 1 is NH 2 or OH; R 2 is H, CN, ##STR6## and R 3 is 2',3'-dideoxy-2',3'-didehydro-β-D-ribofuranose or 2',3'-dideoxyribofuranose.
Claim 2
Independent Claim
79 words
The method of treating human cells infected with a virus selected from the group consisting of herpes virus and cytomegalovirus, said method comprising the step of contacting said cells with a composition comprising a therapeutically effective amount of a compound selected from the group consisting of a compound of the following formula and pharmaceutically acceptable salts thereof: ##STR5## where R 1 is NH 2 or OH; R 2 is H, CN, ##STR6## and R 3 is 2',3'-dideoxy-2',3'-didehydro-β-D-ribofuranose or 2',3'-dideoxyribofuranose.
Claim 3
Dependent Claim
21 words
The method of claim 1 wherein R 1 is NH 2 , R 2 is H and R 3 is 2',3'-dideoxy-2',3'-didehydroribofuranose.
Claim 4
Dependent Claim
21 words
The method of claim 1 wherein R 1 is NH 2 , R 2 is H and R 3 is 2',3'-dideoxyribofuranose.
Claim 5
Dependent Claim
21 words
The method of claim 1 wherein R 1 is NH 2 , R 2 is CN and R 3 is 2',3'-dideoxy-2',3'-didehydroribofuranose.
Claim 6
Dependent Claim
21 words
The method of claim 1 where R 1 is NH 2 , R 2 is CN and R 3 is 2',3'-dideoxyribofuranose.
Claim 7
Dependent Claim
22 words
The method of claim 1 wherein R 1 is NH 2 , R 2 is CONH 2 and R 3 is 2',3'-dideoxy-2',3'-didehydroribofuranose.
Claim 8
Dependent Claim
22 words
The method of claim 1 wherein R 1 is NH 2 , R 2 is CONH 2 and R 3 is 2',3'-dideoxyribofuranose.
Claim 9
Dependent Claim
14 words
The method of claim 1 wherein the virus is human immunodeficiency virus type 1.
Claim 10
Dependent Claim
14 words
The method of claim 1 wherein the virus is herpes simplex virus type 1.
Claim 11
Dependent Claim
11 words
the method of claim 1 wherein the virus is human cytomegalovirus.
Claim 12
Dependent Claim
40 words
A compound selected from the group consisting of compounds of the following general formula and the pharmaceutically acceptable salts thereof: ##STR7## where R 1 is NH 2 or OH; R 2 is ##STR8## and R 3 is 2',3'-dideoxy-2',3'-didehydroribofuranose; or 2',3'-dideoxyribofuranose.
Claim 13
Dependent Claim
40 words
A compound selected from the group consisting of compounds of the following general formula and the pharmaceutically acceptable salts thereof: ##STR7## where R 1 is NH 2 or OH; R 2 is ##STR8## and R 3 is 2',3'-dideoxy-2',3'-didehydroribofuranose; or 2',3'-dideoxyribofuranose.
Claim 14
Dependent Claim
21 words
The compound of claim 11 wherein R 1 is NH 2 , R 2 is ##STR9## and R 3 is 2',3'-dideoxy-2',3'-didehydroribofuranose.
Claim 15
Dependent Claim
21 words
The compound of claim 11 wherein R 1 is NH 2 , R 2 is ##STR10## and R 3 is 2'3'-dideoxyribofuranose.
Claim 16
Dependent Claim
22 words
The compound of claim 12 wherein R 1 is NH 2 , R 2 is CONH 2 and R 3 is 2',3'-dideoxy-2',3'-didehydroribofuranose.
Claim 17
Dependent Claim
22 words
The compound of claim 11 wherein R 1 is NH 2 , R 2 is CONH 2 and R 3 is 2',3'-dideoxyribofuranose.
Claim 18
Dependent Claim
69 words
A treatment composition comprising an effective amount of a compound selected from the group consisting of compounds of the following general formula and pharmaceutically acceptable salts thereof: ##STR11## where R 1 is NH 2 or OH; R 2 is H, CN ##STR12## and R 3 is 2',3'-dideoxy-2',3'-didehydroribofuranose or 2',3'-dideoxyribofuranose, and a pharmaceutically acceptable carrier where R 2 is not H or CN when R 1 is NH 2 .
Claim 19
Dependent Claim
69 words
A treatment composition comprising an effective amount of a compound selected from the group consisting of compounds of the following general formula and pharmaceutically acceptable salts thereof: ##STR11## where R 1 is NH 2 or OH; R 2 is H, CN ##STR12## and R 3 is 2',3'-dideoxy-2',3'-didehydroribofuranose or 2',3'-dideoxyribofuranose, and a pharmaceutically acceptable carrier where R 2 is not H or CN when R 1 is NH 2 .
Claim 20
Dependent Claim
56 words
A compound selected from the group consisting of compounds of the following general formula and the pharmaceutically acceptable salts thereof: ##STR13## where R 1 is NH 2 or OH; R 2 is H, CN, ##STR14## R 3 is 2',3'-dideoxy-2',3'-didehydroribofuranose; or 2',3'-dideoxyribofuranose, where R 2 is not H or CN when R 1 is NH 2 .
Claim 21
Dependent Claim
56 words
A compound selected from the group consisting of compounds of the following general formula and the pharmaceutically acceptable salts thereof: ##STR13## where R 1 is NH 2 or OH; R 2 is H, CN, ##STR14## R 3 is 2',3'-dideoxy-2',3'-didehydroribofuranose; or 2',3'-dideoxyribofuranose, where R 2 is not H or CN when R 1 is NH 2 .
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-01-08 | 1993-07-10 | 1994-01-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-01-08 | 1997-07-10 | 1998-01-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-01-08 | 2001-07-10 | 2002-01-09 | $7700.00 | Window Closed / Lapsed |